548. Combined Results of the Phase 2a/2b/3 Randomized Controlled Trials of Ensitrelvir for the Treatment of COVID-19 Infection

BACKGROUND: Ensitrelvir is a selective SARS-CoV-2 3CL protease inhibitor developed as an oral therapy for the treatment of COVID-19 infection. We report the combined results for ensitrelvir 125 mg and 250 mg treatment from the Phase 2a, 2b, 3 parts of the Phase 2/3 study conducted in patients with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuge, Yuko, Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Yamato, Masaya, Imamura, Takumi, Sonoyama, Takuhiro, Sanaki, Takao, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678521/
http://dx.doi.org/10.1093/ofid/ofad500.617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678521/
http://dx.doi.org/10.1093/ofid/ofad500.617

Ejemplares similares